title: [In vitro activity of biapenem (BIPM) against clinically isolated respiratory pathogens in 1996-1998].
abstract: The in vitro antibacterial activity of biapenem (BIPM), a new carbapenem antibiotic, was compared with those of imipenem (IPM), panipenem (PAPM), meropenem (MEPM), ceftazidime (CAZ) and piperacillin (PIPC) against 280 isolates of 9 respiratory pathogens. The MIC90s of biapenem (BIPM) for methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus pneumoniae, Moraxella catarrhalis, Pseudomonas aeruginosa, and Haemophilus influenzae were 0.12, 32, 0.25, 0.06, 4 and 8 micrograms/ml, respectively. In comparison with other antibiotics, the activity of biapenem (BIPM) for P. aeruginosa was as potent as meropenem (MEPM), but for H. influenzae it was slightly less than those of other antibiotics, and for other respiratory pathogens it was as potent as those of other antibiotics. The MIC90s of biapenem (BIPM) for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens were 0.06, 1, 1, 0.5 microgram/ml, respectively, and which were equal to or somewhat lower than those of other antibiotics. Biapenem (BIPM) showed strong activity against Gram-positive and Gram-negative pathogens, especially P. aeruginosa in general. Based on these results, biapenem (BIPM) is seemed to be highly useful antibiotic for the treatment of respiratory infections with several organism.
authors.affiliation: Department of Respiratory Oncology and Molecular Medicine, Tohoku University.
authors.forename: A
authors.initials: A
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Tokue
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: T
authors.initials: T
authors.lastname: Kikuchi
authors.forename: T
authors.initials: T
authors.lastname: Kobayashi
authors.forename: K
authors.initials: K
authors.lastname: Gomi
authors.forename: S
authors.initials: S
authors.lastname: Fujimura
authors.forename: S
authors.initials: S
authors.lastname: Yasui
authors.forename: T
authors.initials: T
authors.lastname: Nukiwa
authors.forename: S
authors.initials: S
authors.lastname: Shoji
authors.forename: Y
authors.initials: Y
authors.lastname: Honda
mesh_terms: D001419:Bacteria / Q000187:drug effects* / Q000302:isolation & purification / Q000472:pathogenicity; D015780:Carbapenems / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D000077731:Meropenem; D010406:Penicillins / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013845:Thienamycins / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D015780:Carbapenems; D002511:Cephalosporins; D010406:Penicillins; D013845:Thienamycins; D015378:Imipenem; D002442:Ceftazidime; D000077731:Meropenem; C039536:panipenem; D010878:Piperacillin; C065257:biapenem